Literature DB >> 20882354

DLC-1 as a modulator of proliferation, apoptosis and migration in Burkitt's lymphoma cells.

Minhua Feng1, Bo Huang, Zunguo Du, Xiaoping Xu, Zi Chen.   

Abstract

Deleted in liver cancer-1(DLC-1) gene expression is frequently down-regulated or deleted in many types of human cancer. To evaluate whether DLC-1 could be a therapeutic target for non-Hodgkin lymphoma (NHL), we examined the expressions of DLC-1 in Burkitt's lymphoma (BL) cell lines and tested the effects of DLC-1 on cellular growth and migration in BL cells. DLC-1 expression was not detectable in two human BL cell lines, Raji and Daudi, by reverse transcription-PCR. The transfer of DLC-1 into Raji and Daudi cell lines caused a significant inhibition in cell proliferation. This inhibitory effect on cell proliferation in BL cell lines was accompanied by induction of apoptosis. Furthermore, restoration of DLC-1 expression in BL cells had a significant inhibitory effect on migration. Our findings suggest that DLC-1 may play an important role in lymphoma by acting as a bona fide new tumor suppressor gene.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20882354     DOI： 10.1007/s11033-010-0311-z

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN： 0301-4851            Impact factor:   2.316


  27 in total

1.  Role of dephosphorylation of FOXO1 on apoptosis induced by wortmannin for non-Hodgkin's lymphoma cells.

Authors:  Zhan Qiong; Huang Ruofan; Liang Xiaohua; Zhou Xinli; Jiang Jingwei; Chu Zhaohui
Journal:  Mol Biol Rep       Date:  2009-09-11       Impact factor: 2.316

2.  Discovery of novel epigenetic markers in non-Hodgkin's lymphoma.

Authors:  Huidong Shi; Juyuan Guo; Deiter J Duff; Farahnaz Rahmatpanah; Rebecca Chitima-Matsiga; Mufadhal Al-Kuhlani; Kristen H Taylor; Ozy Sjahputera; Melinda Andreski; James E Wooldridge; Charles W Caldwell
Journal:  Carcinogenesis       Date:  2006-06-14       Impact factor: 4.944

3.  Use of the Matrigel-based assay to measure the invasiveness of leukemic cells.

Authors:  M Janiak; H R Hashmi; A Janowska-Wieczorek
Journal:  Exp Hematol       Date:  1994-07       Impact factor: 3.084

4.  DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1.

Authors:  I O Ng; Z D Liang; L Cao; T K Lee
Journal:  Cancer Res       Date:  2000-12-01       Impact factor: 12.701

5.  The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells.

Authors:  Steve Goodison; Jing Yuan; Derek Sloan; Ryung Kim; Cheng Li; Nicholas C Popescu; Virginia Urquidi
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

6.  DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma.

Authors:  Tai Young Kim; Jung Weon Lee; Hwang-Phill Kim; Hyun-Soon Jong; Tae-You Kim; Mira Jung; Yung-Jue Bang
Journal:  Biochem Biophys Res Commun       Date:  2007-01-30       Impact factor: 3.575

7.  Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.

Authors:  Ming Guan; Xiaoling Zhou; Nikolaos Soulitzis; Demetrios A Spandidos; Nicholas C Popescu
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

8.  Overexpression of DLC-1 induces cell apoptosis and proliferation inhibition in the renal cell carcinoma.

Authors:  Tao Zhang; Jingcun Zheng; Ning Jiang; Guozeng Wang; Quan Shi; Chunfang Liu; Yuan Lu
Journal:  Cancer Lett       Date:  2009-04-19       Impact factor: 8.679

9.  Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells.

Authors:  Xiaoling Zhou; Snorri S Thorgeirsson; Nicholas C Popescu
Journal:  Oncogene       Date:  2004-02-12       Impact factor: 9.867

10.  Integrin-mediated signals regulated by members of the rho family of GTPases.

Authors:  E A Clark; W G King; J S Brugge; M Symons; R O Hynes
Journal:  J Cell Biol       Date:  1998-07-27       Impact factor: 10.539
View more
  7 in total

1.  DLC1 as a regulator of proliferation, invasion, cell cycle, and apoptosis in cutaneous squamous cell carcinoma.

Authors:  Cailing Yang; Dapeng Wu; Jinling Jia; Dong Liu; Zhanguo Li; Chunxiao Zhang; Min Li; Yonghua Xia
Journal:  Tumour Biol       Date:  2013-04-28

2.  Effect of small interfering RNA transfection on FAK and DLC1 mRNA expression in OVCAR-3.

Authors:  Huirong Shi; Huina Liu; Guoqiang Zhao
Journal:  Mol Biol Rep       Date:  2012-07-04       Impact factor: 2.316

3.  DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma.

Authors:  Yu-Zheng Xue; Tie-Long Wu; Yan-Min Wu; Ying-Yue Sheng; Zhe-Qiang Wei; Yu-Feng Lu; Li-Hua Yu; Jian-Ping Li; Zhao-Shen Li
Journal:  Tumour Biol       Date:  2013-05-17

4.  Nuclear-targeted deleted in liver cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo.

Authors:  Lo-Kong Chan; Frankie Chi Fat Ko; Karen Man-Fong Sze; Irene Oi-Lin Ng; Judy Wai Ping Yam
Journal:  PLoS One       Date:  2011-09-26       Impact factor: 3.240

5.  Burkitt lymphoma-associated network construction and important network motif analysis.

Authors:  Kunhao Wang; Chao Ma; Chong Xing; Chin-Ling Chen; Zhigang Chen; Yuxia Yao; Jianan Wang; Chunyu Tao
Journal:  Oncol Lett       Date:  2018-06-21       Impact factor: 2.967

6.  Uncovering the rare variants of DLC1 isoform 1 and their functional effects in a Chinese sporadic congenital heart disease cohort.

Authors:  Bin Lin; Yufeng Wang; Zhen Wang; Huilian Tan; Xianghua Kong; Yang Shu; Yuchao Zhang; Yun Huang; Yufei Zhu; Heng Xu; Zhiqiang Wang; Ping Wang; Guang Ning; Xiangyin Kong; Guohong Hu; Landian Hu
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

7.  Deleted in liver cancer 1 expression and localization in hepatocellular carcinoma tissue sections.

Authors:  Dominika Wolosz; Agnieszka Walczak; Grzegorz M Wilczynski; Grzegorz Szparecki; Ewa Wilczek; Barbara Gornicka
Journal:  Oncol Lett       Date:  2014-06-03       Impact factor: 2.967
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.